JP2020510061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510061A5 JP2020510061A5 JP2019550583A JP2019550583A JP2020510061A5 JP 2020510061 A5 JP2020510061 A5 JP 2020510061A5 JP 2019550583 A JP2019550583 A JP 2019550583A JP 2019550583 A JP2019550583 A JP 2019550583A JP 2020510061 A5 JP2020510061 A5 JP 2020510061A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000003839 salts Chemical class 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 41
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000004043 oxo group Chemical group O=* 0.000 claims 22
- 125000004429 atom Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- -1 C 2 to C 6 alkynyl Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000001345 alkine derivatives Chemical class 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 108010024121 Janus Kinases Proteins 0.000 claims 2
- 102000015617 Janus Kinases Human genes 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- AEOMLJVHGODKEW-UHFFFAOYSA-N CCc(cc(cc1)Cl)c1OC(F)F Chemical compound CCc(cc(cc1)Cl)c1OC(F)F AEOMLJVHGODKEW-UHFFFAOYSA-N 0.000 description 1
- VDYDAUQHTVCCBX-UHFFFAOYSA-N Cc(cc(cc1)Cl)c1OC Chemical compound Cc(cc(cc1)Cl)c1OC VDYDAUQHTVCCBX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/076598 | 2017-03-14 | ||
| CN2017076598 | 2017-03-14 | ||
| PCT/EP2018/056129 WO2018166993A2 (en) | 2017-03-14 | 2018-03-13 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510061A JP2020510061A (ja) | 2020-04-02 |
| JP2020510061A5 true JP2020510061A5 (enExample) | 2021-04-22 |
Family
ID=61655767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550583A Ceased JP2020510061A (ja) | 2017-03-14 | 2018-03-13 | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200002346A1 (enExample) |
| EP (1) | EP3596072B1 (enExample) |
| JP (1) | JP2020510061A (enExample) |
| CN (1) | CN110494434B (enExample) |
| WO (1) | WO2018166993A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7256757B2 (ja) | 2017-05-22 | 2023-04-12 | エフ． ホフマン－ラ ロシュ アーゲー | 処置用化合物及び組成物、並びにその使用方法 |
| JP7657740B2 (ja) | 2019-06-18 | 2025-04-07 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｊａｋキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用 |
| CN114026096B (zh) | 2019-06-18 | 2025-02-07 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
| WO2022256358A1 (en) * | 2021-06-03 | 2022-12-08 | Genentech, Inc. | Process for preparing medicaments |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| AU2002361992A1 (en) | 2001-12-20 | 2003-07-09 | Bayer Aktiengesellschaft | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| WO2006070202A1 (en) * | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| JP5474354B2 (ja) * | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US8435970B2 (en) * | 2006-06-29 | 2013-05-07 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
| JP2009542608A (ja) * | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| AU2009259853A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| BRPI0914404A2 (pt) * | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| CA2929316C (en) * | 2013-11-08 | 2021-12-28 | Takeda Pharmaceutical Company Limited | Pyrazole for the treatment autoimmune disorders |
| HRP20210935T1 (hr) | 2014-05-23 | 2021-08-06 | F. Hoffmann - La Roche Ag | Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak |
| WO2017140825A1 (en) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
-
2018
- 2018-03-13 JP JP2019550583A patent/JP2020510061A/ja not_active Ceased
- 2018-03-13 WO PCT/EP2018/056129 patent/WO2018166993A2/en not_active Ceased
- 2018-03-13 CN CN201880017772.2A patent/CN110494434B/zh not_active Expired - Fee Related
- 2018-03-13 EP EP18711294.1A patent/EP3596072B1/en active Active
-
2019
- 2019-09-05 US US16/561,447 patent/US20200002346A1/en not_active Abandoned
-
2021
- 2021-02-12 US US17/174,733 patent/US11649241B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505529A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| RU2526201C2 (ru) | Способ лечения артрита | |
| JP2013542261A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2014530900A5 (enExample) | ||
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| JP2005502643A5 (enExample) | ||
| JP2016510804A (ja) | 複合製剤 | |
| JP2019516739A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| JP2023512664A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2019520344A5 (enExample) | ||
| JP2017526724A5 (enExample) | ||
| JP2022529061A5 (enExample) | ||
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| JP2005508872A5 (enExample) |